Post-Inflammatory Hyperpigmentation (PIH): What Clinical Studies Reveal About Lasers, Peels, and Topicals

Few skin conditions are as frustrating as post-inflammatory hyperpigmentation (PIH). Just as an acne lesion, eczema flare-up, or minor cutaneous injury finally heals, it leaves behind a stubborn brown or dark patch. While PIH is not a medically dangerous condition, the dark marks can persist for months or even years, causing significant emotional distress, lower self-confidence, and a reduced quality of life.

PIH is particularly prevalent among individuals with darker skin phototypes (Fitzpatrick skin types III–VI), who have higher baseline amounts of eumelanin and more reactive melanocytes. In clinical populations, up to 65% of African American, 48% of Hispanic, and 53% of Asian patients develop PIH secondary to acne vulgaris.

While the skincare market is flooded with spot correctors, chemical peels, and laser treatments, what does the clinical literature actually reveal about their effectiveness? This article reviews recent systematic clinical evidence to highlight which treatments work, which fall short, and why combining modalities offers the best path to clear skin.

1. The Pathophysiology: Why Do Dark Marks Form?

To understand why PIH is so stubborn, we must look at what occurs beneath the skin surface during an inflammatory insult:

[ Cutaneous Injury / Acne / Eczema ]
                  │
                  ▼
   [ Release of Inflammatory Mediators ]
(Prostaglandins, Leukotrienes, Histamine, ROS)
                  │
                  ▼
   [ Hyperactivation of Melanocytes ]
(Upregulated Tyrosinase & Melanosome Synthesis)
                  │
        ┌─────────┴─────────┐
        ▼                   ▼
[ Epidermal PIH ]     [ Dermal PIH ]
(Keratinocyte accumulation) (Basement membrane breakdown;
                             Dermal melanophages)

1. The Inflammatory Cascade: When the skin suffers trauma or inflammation, surrounding cells release chemical mediators, including prostaglandins (PGE2), leukotrienes (LTC4, LTD4), histamine, thromboxane B2, and reactive oxygen species (ROS). These signals directly stimulate basal melanocytes, expanding their cellular dendrites and upregulating the rate-limiting enzyme tyrosinase.

2. Epidermal vs. Dermal Deposition:

• Epidermal PIH: Excess melanin accumulates within surrounding epidermal keratinocytes. Because these surface cells naturally desquamate over time, epidermal PIH responds well to topical tyrosinase inhibitors and exfoliating agents.
• Dermal PIH: Severe inflammation damages the delicate dermo-epidermal basement membrane, allowing melanin granules to spill into the papillary dermis. There, dermal macrophages engulf the pigment to become melanophages. Dermal melanophages can remain trapped in the dermal matrix for years, making dermal PIH resistant to standard surface creams.

2. Systematic Evidence: Evaluating Clinical Treatment Outcomes

A landmark systematic review by Kashetsky et al. (2024) evaluated treatment outcomes across 41 clinical studies representing 877 PIH patients. Over 93% of studied patients possessed darker skin phototypes (Fitzpatrick III–VI), with facial acne vulgaris serving as the primary cause of PIH in roughly 70% of cases.

The review evaluated four primary treatment categories: topicals, lasers/energy-based devices, chemical peels, and combination therapies.

                     ┌───────────────────────────┐
                     │   PIH RESPONSE RATES      │
                     └─────────────┬─────────────┘
                                   │
         ┌─────────────────────────┼─────────────────────────┐
         ▼                         ▼                         ▼
  [ TOPICAL MONOTHERAPY ]   [ LASERS & ENERGY DEVICES ]   [ COMBINATION THERAPIES ]
  • Complete: 5.4%          • Complete: 18.1%             • Complete: 2.4%
  • Overall: 77.8%          • Overall: 79.3%              • Overall: 87.3%
  • (Azelaic Acid 100%)     • (IPL 84.7%, Nd:YAG 79.6%)   • (Laser+Topicals 88.1%)

A. Complete Resolution Is Rare Across All Monotherapies

One of the most striking findings from clinical trial data is that complete clearance of PIH is rarely achieved by any single treatment modality alone:

• Lasers & Energy-Based Devices: Achieved complete clearance in 18.1% of patients.
• Topical Monotherapies: Achieved complete clearance in 5.4% of patients.
• Combination Therapies: Achieved complete clearance in 2.4% of patients.
• Chemical Peels Alone: Achieved 0% complete clearance in the systematic review table.

However, when looking at overall clinical improvement (combining complete and partial responses), response rates are significantly higher, demonstrating that proper treatment reliably lightens marks even if total erasure takes longer.

3. Deep-Dive: Topical Monotherapy Performance

Topical agents represent the first line of defense for PIH due to their accessibility, ease of use, and low risk of triggering further inflammatory hyperpigmentation. Overall improvement with topicals reached 77.8%, but individual active ingredients varied dramatically:

• Azelaic Acid (15% Gel): Emerged as the single best-performing topical monotherapy for PIH. It achieved a 30.0% complete response rate and a 70.0% partial response rate—resulting in a 100% overall improvement rate with zero non-responders. Because azelaic acid selectively targets hyperactive melanocytes without lightening normal background skin, it is ideal for discrete acne spots.
• Vitamin C Derivatives: Demonstrated a 29.4% complete response rate and 26.5% partial response rate. Formulations utilizing stable complexes (such as glyceryl-octyl-ascorbic acid and ascorbyl phosphate) achieved total clearance in 100% of small trial cohorts.
• Topical Retinoids (Adapalene 0.1%–0.3%, Tretinoin 0.1%): Showed a 74.2% overall improvement rate (4.1% complete, 70.1% partial). Retinoids accelerate epidermal cell turnover to clear surface melanin while suppressing MSH-induced melanogenesis.
• Bakuchiol (0.5% Cream): Produced a 62.5% partial response rate in acne-induced PIH within 4 weeks, offering a gentle, botanical alternative for sensitive skin.
• Hydroquinone Monotherapy: Surprisingly, single-agent hydroquinone (4%) performed poorly in PIH systematic reviews, with 62.5% of patients showing poor to no response. Furthermore, hydroquinone carries the risk of inducing halo hypopigmentation around small acne spots or triggering secondary PIH if irritation develops.

4. Lasers and Energy-Based Devices: High Power, High Precision

Laser and light-based therapies target melanin through selective photothermolysis and photoacoustic destruction, making them capable of shattering both epidermal pigment and deeper dermal melanophages.

• QS Nd:YAG 1064 nm Laser: The most widely studied laser for PIH in darker skin phototypes. Because the 1064 nm wavelength penetrates deep into the dermis while sparing epidermal water and melanin, it achieved a 29.6% complete response rate and 50.0% partial response rate (79.6% overall improvement).
• Intense Pulsed Light (IPL): Delivered an 84.7% partial response rate.
• Pulsed-Dye Lasers (510–595 nm): Achieved a 50.0% to 54.5% complete response rate by simultaneously targeting hyperactive melanocytes and vascular inflammatory components.

⚠️ A Critical Warning on QS Ruby Lasers: Not all lasers are safe for PIH. The Q-Switched Ruby Laser (694 nm) resulted in worsening of PIH in 44.4% of patients due to excessive epidermal melanin absorption and subsequent thermal injury. Low-fluence QS Nd:YAG lasers also caused mild worsening in 2.6% of cases when parameters were improperly set.

5. The Gold Standard Strategy: Combination Therapies

Because PIH involves both ongoing epidermal pigment synthesis and trapped dermal melanophages, combination therapies achieved the highest overall rates of clinical success (87.3% to 88.1%):

1. Laser + Topical Regimens (88.1% Improvement): Combining a low-fluence 1064 nm QS Nd:YAG laser or picosecond laser with topical cysteamine 5%, tranexamic acid, or azelaic acid achieved near-100% partial response rates. The laser shatters deep dermal melanophages while topical tyrosinase inhibitors prevent new pigment synthesis.

2. Peels + Topical Regimens (85.7% Improvement): While superficial salicylic acid (SA) peels alone had a 66.7% failure rate, combining 20%–30% SA peels or glycolic acid peels with topical tretinoin or vitamin C increased partial response rates to 73.3%–96.8%. Peels exfoliate the stratum corneum, enhancing the penetration of co-applied topical actives.

6. Summary Comparison of PIH Treatment Modalities

7. Practical Takeaways for Managing PIH

1. Treat the Primary Cause First: Always control active acne vulgaris, eczema, or skin inflammation before initiating aggressive pigment treatments. Preventing new inflammatory lesions is the single most effective way to halt ongoing PIH.

2. Prioritize Azelaic Acid and Retinoids: Start with topical 15% azelaic acid gel or adapalene 0.1% gel as foundational daily treatments.

3. Always Wear Tinted Sunscreen: Photoprotection is essential. Broad-spectrum tinted sunscreens containing iron oxides protect against visible light and long-wavelength UVA, preventing dark marks from darkening further.

4. Avoid Aggressive Monotherapies: Avoid high-strength single-agent hydroquinone or harsh standalone peels, which carry higher risks of rebound irritation. For recalcitrant cases, opt for low-fluence Nd:YAG lasers paired with gentle topical tyrosinase inhibitors.

References

• Agbai, O., Hamzavi, I., & Jagdeo, J. (2017). Laser treatments for postinflammatory hyperpigmentation: a systematic review. JAMA Dermatology, 153(2), 199–206.
• Callender, V. D., Baldwin, H., Cook-Bolden, F. E., Alexis, A. F., Stein Gold, L., & Guenin, E. (2022). Effects of topical retinoids on acne and post-inflammatory hyperpigmentation in patients with skin of color. American Journal of Clinical Dermatology, 23(1), 69–81.
• Jafry, M., Guan, L. L., & Mohammad, T. F. (2024). A practical guide to over-the-counter treatments for hyperpigmentation. JEADV Clinical Practice, 3(2), 433–447.
• Kashetsky, N., Feschuk, A., & Pratt, M. E. (2024). Post-inflammatory hyperpigmentation: A systematic review of treatment outcomes. Journal of the European Academy of Dermatology and Venereology, 38(3), 470–479.
• Kircik, L. H. (2011). Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne. Journal of Drugs in Dermatology, 10(6), 586–590.
• Nautiyal, A., & Wairkar, S. (2021). Management of hyperpigmentation: Current treatments and emerging therapies. Pigment Cell & Melanoma Research, 34(6), 1000–1014.
• Vashi, N. A., & Kundu, R. V. (2013). Facial hyperpigmentation: causes and treatment. British Journal of Dermatology, 169(Suppl. 3), 41–56.